Innovative nanotechnological RNA delivery systems targeting the direct cause of Alzheimer‘s disease instead of its symptoms
Neurodegenerative diseases such as Alzheimer’s affect over 7 million people in Europe. Despite this fact, few treatments for this group of diseases are available so far. Nanomedical approaches can make a difference, providing new therapeutic options by helping drugs to enter the brain.
Therefore, the multinational research project B-SMART sets out to provide an RNA-based therapy perspective for neurodegenerative diseases targeting the direct cause of the disease instead of its symptoms in the midterm.
Learn about our ideas and objectives: The animated B-SMART film
Alzheimer's disease from bench to bed
News & Events
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced that they have achieved...Read more
"Transferring RNA therapeutics to the brain crossing the blood-cerebrospinal fluid barrier is a unique research endeavor. Finding a novel gateway to transport RNA to the brain will enable the development of causal therapies not only for Alzheimer’s, but for other diseases as well."
Lack of causal therapies and effective drugs
RNA-based nanomedicines directly targeting the brain
Secure in-vivo transport through nanocarriers
Crossing the blood-cerebrospinal fluid barrier through ligands
Basis technology for treatment of other diseases